No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
314 |
4. Check minimum number of eventsNone |
314 |
5. Include endpointsNone |
314 |
6. Filter based on genotype QC (FinnGen only) |
304 |
Control definitions (FinnGen only)
- Control exclude
- G6_POLYNEU
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- G62
- Name in latin
- Polyneuropathia medicamento provocata
Similar endpoints
↥List of similar endpoints to
Drug-induced polyneuropathy
based on the number of shared cases.
Similar with more cases:
- Polyneuropathies and other disorders of the peripheral nervous system
- Neurological diseases
- Neurological diseases, wide definition
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1549 | 841 | 700 |
| Only index persons | 1345 | 745 | 600 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.03 | 0.03 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 62.86 | 64.41 | 60.97 |
| Only index persons | 63.08 | 64.55 | 61.25 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 304 | 163 | 141 |
| Unadjusted period prevalence (%) | 0.06 | 0.06 | 0.06 |
| Median age at first event (years) | 62.53 | 63.54 | 61.36 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 314
- Matched controls
- 3140
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G62.0
ICD-10 Finland
Drug-induced polyneuropathy
4503599627370496.0
307.7
310
*
H02AB02
ATC
dexamethasone; systemic
14.4
128.3
164
221
128
Kela drug reimbursment
Cancers of female genital organs
27.7
83.1
59
26
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
14.5
82.6
84
77
G62.9
ICD-10 Finland
Polyneuropathy, unspecified
142.7
81.6
84
8
A04AA01
ATC
ondansetron; systemic, rectal
10.2
78.3
109
155
L03AA02
ATC
filgrastim; parenteral
16.5
71.2
65
49
A03FA01
ATC
metoclopramide; systemic, rectal
7.2
69.0
172
452
ZX120
NOMESCO Finland
Intravenous
7.9
58.6
100
176
L03AA13
ATC
pegfilgrastim; parenteral
10.8
54.3
65
74
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
10.2
51.2
64
77
N02AA05
ATC
oxycodone; systemic
5.8
50.2
133
354
N03AX16
ATC
[U] pregabalin
5.4
48.1
153
473
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
11.0
48.1
56
61
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
9.8
46.9
60
74
XW000
NOMESCO Finland
Bone marrow biopsy
10.0
44.8
56
67
WB123
NOMESCO Finland
Demanding adjuvant cytostatic therapy
19.6
43.5
35
20
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
17.3
43.3
37
24
JN4BD
NOMESCO Finland
Extensive body CT
6.0
41.4
90
197
WW500
NOMESCO Finland
Blood transfusion
9.2
40.0
53
68
A04AA02
ATC
granisetron; systemic, transdermal
7.6
39.2
62
98
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
9.3
37.8
49
61
R50.9
ICD-10 Finland
Fever, unspecified
4.4
31.9
105
319
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
5.9
30.3
62
126
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
11.4
30.3
33
32
JN4AD
NOMESCO Finland
Body CT examination
5.1
29.4
73
176
TPX10
NOMESCO Finland
Implantation of vascular injection port
9.2
28.8
37
45
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
10.4
27.5
32
34
A04AA55
ATC
palonosetron, combinations; systemic
8.2
26.9
38
52
N06AX21
ATC
duloxetine; oral
4.8
26.8
71
180
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.2
26.3
88
267
N03AX12
ATC
[U] gabapentin; oral
3.9
26.2
100
333
N02BF02
ATC
pregabalin; oral
6.5
25.9
46
81
B01AB05
ATC
enoxaparin; parenteral
3.4
25.8
156
700
L01BC06
ATC
capecitabine; oral
7.3
24.9
39
60
130
Kela drug reimbursment
Malignant tumour
4.7
24.9
66
167
Z51.5
ICD-10 Finland
Palliative care
5.1
24.9
59
136
ZX112
NOMESCO Finland
Subcutaneous
9.0
22.6
29
35
B01AB10
ATC
tinzaparin; parenteral
4.4
22.5
65
175
WZC00
NOMESCO Finland
Treatment plan or consultation
3.2
22.5
166
821
WX302
NOMESCO Finland
Thoracal epidural anesthesy
6.0
20.0
38
71
WF049
NOMESCO Finland
Radiotherapy of metastasis
6.7
19.8
33
54
L04AX04
ATC
lenalidomide; oral
43.2
19.8
24
6
153
Kela drug reimbursment
Lenalidomid
43.2
19.8
24
6
G62.8
ICD-10 Finland
Other specified polyneuropathies
106.5
18.8
20
*
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
5.0
18.1
42
94
LX1AE
NOMESCO Finland
Gynecological ultrasound examination as part of clinical examination
4.5
18.0
49
125
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
4.6
17.9
46
112
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.8
17.9
193
1128
C90.0
ICD-10 Finland
Multiple myeloma
20.1
17.6
26
14
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
18.8
17.2
26
15
C91.0
ICD-10 Finland
Acute lymphoblastic leukaemia [ALL]
53.2
17.2
20
*
C56.71
ICD-10 Finland
Serous epithelial malignant tumor of the ovary
23.5
17.1
24
11
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
4.6
17.0
44
108
JAL30
NOMESCO Finland
Omentectomy
21.5
16.7
24
12
N02BF01
ATC
gabapentin; oral
4.3
16.5
47
124
329
Kela drug reimbursment
Lenalidomide
63.4
15.9
18
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.7
15.8
143
752
XX3DW
NOMESCO Finland
Time consuming IT work
3.4
15.7
64
217
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
15.9
15.6
25
17
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.9
15.4
50
145
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
30.4
15.4
20
7
ZX121
NOMESCO Finland
Central venous catheter
21.4
15.3
22
11
ZXE10
NOMESCO Finland
More than one and less than three hours
2.6
15.1
152
837
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.4
14.3
60
206
A02BC02
ATC
pantoprazole; systemic
2.9
14.3
241
1683
H02AB09
ATC
hydrocortisone; systemic
5.7
14.0
27
51
L02BG04
ATC
letrozole; oral
4.1
13.9
41
111
ZXD05
NOMESCO Finland
Urgent procedure
2.6
13.7
116
583
C54.11
ICD-10 Finland
Adenocarcinoma of the endometrium
11.7
13.3
24
22
R4110
NOMESCO Finland
Physiotherapy
2.5
13.2
126
668
Z94.8
ICD-10 Finland
Other transplanted organ and tissue status
29.8
13.1
17
6
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
5.5
12.9
26
51
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
4.0
12.8
39
108
D70.82
ICD-10 Finland
Drug-induced neutropenia
11.7
12.7
23
21
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.8
12.7
79
339
WX408
NOMESCO Finland
General anesthesy, balanced
2.5
12.6
113
579
WW300
NOMESCO Finland
Transfer of autologic stem cells
25.6
12.6
17
7
9732/3-C42.1
ICD-O-3
Plasma cell myeloma of bone marrow
19.0
12.2
18
10
N03AX09
ATC
lamotrigine; oral
5.3
12.2
25
50
TAB00
NOMESCO Finland
Lumbar puncture
4.3
12.0
32
80
8461/3-C56.9
ICD-O-3
High grade serous carcinoma of ovary
48.6
12.0
14
*
ZX131
NOMESCO Finland
Intrathecal
67.5
11.7
13
*
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
4.8
11.7
27
60
C78.6
ICD-10 Finland
Secondary malignant neoplasm of retroperitoneum and peritoneum
36.5
11.4
14
*
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
9.8
11.2
22
24
R19.0
ICD-10 Finland
Intra-abdominal and pelvic swelling, mass and lump
9.8
11.2
22
24
TPH07
NOMESCO Finland
Cathetrisation of artery
3.0
11.2
56
213
B01AB04
ATC
dalteparin; parenteral
4.7
10.9
26
59
J05AB11
ATC
valaciclovir; oral
2.8
10.9
65
271
LAF10
NOMESCO Finland
Bilateral salpingo-oophorectomy
5.6
10.7
21
40
UJF32
NOMESCO Finland
Coloscopy
2.3
10.7
105
554
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.1
10.7
48
171
PJD64
NOMESCO Finland
Laparoscopic dissection of iliac lymph nodes
14.9
10.6
17
12
R4190
NOMESCO Finland
Nutritional therapy
3.8
10.5
33
93
1XX02, ,
NOMESCO Finland
113.7
10.5
11
*
C56
ICD-10 Finland
Malignant neoplasm of ovary
24.3
10.3
14
6
ZXE02
NOMESCO Finland
Procedure duration 10 to 19 minutes
4.0
10.3
30
80
Z3226
NOMESCO Finland
Physiotherapist
2.4
10.2
86
423
A05AA02
ATC
ursodeoxycholic acid; oral
11.9
10.2
18
16
WF003
NOMESCO Finland
Adjuvant radiotherapy
5.1
10.2
22
46
ZXE30
NOMESCO Finland
More than five and less than seven hours
3.9
10.1
31
86
TPH04
NOMESCO Finland
Cathetrisation of vein
2.4
10.1
90
455
PJD63
NOMESCO Finland
Laparoscopic dissection of aortic lymph nodes
41.5
10.0
12
*
WX402
NOMESCO Finland
General anaesthesia
2.4
10.0
89
449
M04AA01
ATC
allopurinol; systemic
2.8
10.0
56
226
393
Kela drug reimbursment
Pomalidomide
56.8
9.7
11
*
1507
Kela drug reimbursment
Pomalidomide
56.8
9.7
11
*
H02AB06
ATC
prednisolone; systemic
2.1
9.7
166
1086
A41.9
ICD-10 Finland
Sepsis, unspecified
5.0
9.7
21
44
WW402
NOMESCO Finland
Leucoferesis
103.0
9.5
10
*
N06AX16
ATC
venlafaxine; oral
2.7
9.5
59
251
ZXE20
NOMESCO Finland
More than three and less than five hours
2.5
9.4
67
304
Y57
ICD-10 Finland
Adverse effects in the therapeutic use of other and unspecified drugs and medicaments
10.0
9.4
18
19
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.1
9.2
128
770
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
5.0
9.2
20
42
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.4
9.2
71
335
L01BB02
ATC
mercaptopurine; oral
12.0
9.2
16
14
ZXE03
NOMESCO Finland
Procedure duration 20 to 29 minutes
3.6
9.2
31
92
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
7.2
9.0
21
31
WD515
NOMESCO Finland
Demanding therapy of malignancy with enzyme inhibitors and similar treatments
24.9
9.0
12
5
ZX080
NOMESCO Finland
Image guided radiotherapy
5.1
9.0
19
39
ZXE00
NOMESCO Finland
One hour or less
2.1
8.9
145
922
ZXE11
NOMESCO Finland
Procedure duration 60 to 89 minutes
3.3
8.8
34
110
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
14.6
8.8
14
10
JEA00
NOMESCO Finland
Appendectomy
3.7
8.7
29
85
L04AX06
ATC
pomalidomide; oral
51.5
8.7
10
*
L03AA14
ATC
lipegfilgrastim; parenteral
7.3
8.7
20
29
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
9.4
8.6
17
19
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
2.0
8.6
147
949
LAF11
NOMESCO Finland
Laparoscopic bilateral salpingo-oophorectomy
3.8
8.5
26
72
J01DB01
ATC
cefalexin; oral
2.5
8.5
265
2139
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
4.9
8.5
19
41
N04BC05
ATC
pramipexole; oral
3.1
8.5
38
135
1XX32, ,
NOMESCO Finland
92.4
8.5
9
*
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.2
8.4
87
465
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.1
8.3
101
574
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.1
8.3
37
131
GD1AD
NOMESCO Finland
Thorax CT examination
3.4
8.2
31
99
C56.00
ICD-10 Finland
Malignant tumor of the ovary without histology
17.8
8.1
12
7
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
10.4
8.1
15
15
Z2446
NOMESCO Finland
Social worker
2.9
8.1
41
156
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
3.2
7.9
33
112
J01MA12
ATC
levofloxacin; systemic
2.3
7.9
72
363
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.1
7.8
92
514
LCD01
NOMESCO Finland
Total laparoscopic hysterectomy
7.7
7.8
17
23
N02AX02
ATC
tramadol; systemic, rectal
2.0
7.7
149
993
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
12.3
7.6
13
11
JA3AT
NOMESCO Finland
Cathetrisation of abdominal cavity with ultrasound guidance
9.2
7.6
15
17
WZC30
NOMESCO Finland
Teaching
2.3
7.6
66
326
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
3.2
7.5
30
99
N17.9
ICD-10 Finland
Acute renal failure, unspecified
4.6
7.5
18
41
LAF16
NOMESCO Finland
Excision of uterus, adnexes and lymph nodes for treatment of ovarian cancer
13.8
7.4
12
9
C20.91
ICD-10 Finland
Malignant tumor of the rectum invasive carcinoma
7.1
7.4
17
25
A04AD12
ATC
aprepitant; systemic
6.5
7.4
18
29
WW200
NOMESCO Finland
Immunization
6.1
7.3
19
33
Z63.7
ICD-10 Finland
Other stressful life events affecting family and household
4.5
7.3
18
42
Z3231
NOMESCO Finland
Registered nurse
2.0
7.2
112
689
FM2CE, ,
NOMESCO Finland
6.8
7.2
17
26
WF004
NOMESCO Finland
Palliative radiotherapy
6.8
7.2
17
26
ZXM00
NOMESCO Finland
Intraoperative use of ultrasonographic imaging
30.8
7.2
9
*
WB401
NOMESCO Finland
Simple antibody therapy of primary tumour
10.4
7.1
13
13
ZX114
NOMESCO Finland
Intramuscular
7.3
7.1
16
23
Z2221
NOMESCO Finland
Medical doctor
2.0
7.1
99
587
115
Kela drug reimbursment
Breast cancer
2.7
7.0
38
150
J05AB01
ATC
aciclovir; systemic
2.1
7.0
82
456
127
Kela drug reimbursment
Transplant complication
7.8
7.0
15
20
JN3CG
NOMESCO Finland
Extensive MRI examination of abdomen with high intensity magnet
14.2
6.9
11
8
JN4CD
NOMESCO Finland
Very extensive body CT
4.0
6.9
20
53
PJD52
NOMESCO Finland
Block dissection of axillary lymph nodes
4.0
6.9
20
53
WB121
NOMESCO Finland
Demanding neoadjuvant cytostatic therapy
9.6
6.8
13
14
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
3.5
6.8
24
73
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.4
6.8
50
229
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
2.8
6.7
35
135
UJF45
NOMESCO Finland
Flexible sigmoidoscopy with biopsy
2.8
6.6
34
130
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
3.3
6.6
25
80
N05CD07
ATC
temazepam; oral
2.5
6.6
44
193
HAC20
NOMESCO Finland
Total mastectomy
3.7
6.6
21
60
QBB10
NOMESCO Finland
Major dressing of wound of skin of trunk
4.1
6.5
18
46
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
6.8
6.4
15
23
ZYC01
NOMESCO Finland
Remote contact by phone
3.0
6.3
29
104
WC401
NOMESCO Finland
Simple antibody therapy of local recurrence of tumour
+∞
6.3
6
*
WW306
NOMESCO Finland
Transfer of stem cells from foreign registered donator
+∞
6.3
6
*
3AA13, ,
NOMESCO Finland
27.3
6.3
8
*
9835/3-C42.1
ICD-O-3
Precursor cell lymphoblastic leukemia, NOS, of bone marrow
27.3
6.3
8
*
ZXC96
NOMESCO Finland
Robot assisted procedure
5.4
6.1
17
33
A79
ICPC
Malignancy NOS
6.9
6.1
14
21
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
94
224
5.56
39.19
10.1
2.8
65.01
66.00
g/l
0.61
87
205
251
1383
5.06
32.90
19.8
6.4
9.67
11.45
umol/l
3.58
245
1308
102
313
4.35
30.43
11.7
3.9
250.24
244.76
u/l
0.15
102
299
214
1124
3.84
28.20
13.4
5.3
34.31
35.50
g/l
2.34
206
1050
93
290
4.14
26.81
6.1
4.1
4.50
23.09
ug/l
0.69
77
241
258
1589
4.50
25.67
39.6
9.9
3.49
4.05
e9/l
4.26
239
1369
38
57
7.45
24.81
10.4
10.6
193.57
133.17
iu/ml
—
7
12
178
904
3.24
23.25
6.9
3.4
2.36
2.36
mmol/l
0.07
166
788
104
395
3.44
21.89
14.3
7.1
1.05
1.12
mmol/l
1.88
97
366
218
1308
3.18
20.22
18.3
6.5
1.21
1.22
mmol/l
1.33
207
1193
64
186
4.07
19.91
2.0
1.7
—
—
—
0
0
227
1411
3.20
19.43
19.4
7.5
1.20
1.22
mmol/l
2.24
196
1222
286
2068
5.29
18.98
20.3
7.3
88.62
85.89
u/l
0.42
280
1916
42
91
5.17
18.83
14.0
1.3
8.62
10.32
g/l
1.63
36
83
24
8
32.32
18.62
1.1
1.6
—
—
—
0
0
43
96
5.03
18.62
13.7
1.3
6.88
7.58
g/l
1.98
37
89
43
96
5.03
18.62
13.7
1.3
3.57
3.65
g/l
0.05
37
89
43
96
5.03
18.62
13.7
1.3
—
—
—
0
0
102
420
3.12
18.37
2.5
1.9
—
—
—
0
0
240
1568
3.25
18.27
13.6
4.9
6.48
6.67
mmol/l
0.80
233
1476
97
391
3.14
18.09
2.8
2.5
2.28
2.35
g/l
0.68
91
360
207
1254
2.91
17.97
13.7
12.2
1.13
1.25
inr
1.92
66
342
157
829
2.79
17.72
4.8
2.4
54.19
61.95
u/l
0.62
146
761
92
378
3.03
16.42
2.9
2.6
22.19
21.41
%
0.21
83
333
39
89
4.86
16.41
13.6
1.3
2.73
3.12
g/l
1.66
33
82
25
38
7.06
15.99
3.6
1.6
—
—
—
0
0
79
302
3.16
15.94
2.6
1.8
—
—
—
0
0
38
87
4.83
15.92
14.5
1.6
1.81
0.48
g/l
0.95
30
78
36
79
5.02
15.85
2.8
2.2
13.76
21.74
iu/l
0.93
22
59
195
1197
2.66
15.62
5.4
2.7
—
—
—
0
0
78
305
3.07
15.07
2.6
1.9
—
—
—
0
0
35
79
4.86
14.89
3.0
2.1
8.00
7.60
u/l
0.06
20
58
201
1281
2.58
14.43
34.1
10.4
0.00
0.00
e9/l
0.61
184
1039
81
334
2.92
14.16
10.2
3.4
7.65
8.84
umol/l
0.18
71
293
204
1322
2.55
13.93
24.1
6.6
55.87
55.90
%
0.01
197
1246
202
1310
2.52
13.67
25.0
6.6
2.67
2.93
%
0.94
196
1226
154
884
2.46
13.64
5.7
3.6
58.78
131.68
e6/l
0.42
131
689
130
693
2.49
13.52
8.1
2.7
320.47
7506.90
umol/l
3.30
123
596
204
1343
2.48
13.14
25.0
6.8
27.77
28.98
%
0.68
197
1261
67
261
2.99
12.88
3.9
2.3
27.79
29.00
u/l
0.17
58
216
33
81
4.44
12.65
3.1
1.7
—
—
—
0
0
242
1743
2.69
12.57
6.8
4.6
11.29
2443.03
e6/l
—
7
32
116
604
2.46
12.52
4.0
2.8
6.45
4.20
e6/l
0.53
106
543
33
82
4.38
12.45
15.1
1.3
37.99
37.32
g/l
0.32
27
75
28
61
4.94
12.38
3.3
1.6
—
—
—
0
0
24
27
9.53
11.98
6.4
4.0
—
—
—
0
0
32
81
4.29
11.79
1.3
1.3
—
—
—
0
0
140
813
2.30
11.59
5.7
3.5
0.40
0.39
e6/l
0.04
119
619
148
881
2.29
11.54
10.1
3.3
33.97
33.00
u/l
0.17
143
837
165
1029
2.27
11.48
5.7
3.5
—
—
—
0
0
111
587
2.38
11.39
6.2
1.9
2.19
1.30
mg/l
0.39
90
471
32
84
4.13
11.24
3.0
1.7
—
—
—
0
0
27
62
4.67
11.21
13.5
1.7
8.95
6.98
e6/l
0.08
21
51
27
62
4.67
11.21
13.5
1.8
5.05
206.43
e6/l
1.29
21
51
23
46
5.32
11.18
2.8
1.7
—
—
—
0
0
23
46
5.32
11.18
2.8
1.7
—
—
—
0
0
168
1076
2.21
10.71
4.2
2.8
237.74
135.20
ug/l
2.14
154
989
94
473
2.41
10.69
4.9
3.4
1.58
2.22
e6/l
0.52
68
268
24
52
4.91
10.66
3.3
1.5
—
—
—
0
0
29
75
4.16
10.38
3.6
2.7
—
—
—
0
0
73
341
2.49
9.68
19.6
7.0
103.78
103.79
mmol/l
0.00
73
341
18
18
10.53
9.65
4.5
6.2
—
—
—
0
0
18
18
10.53
9.65
4.5
6.2
—
—
—
0
0
25
61
4.37
9.63
2.7
1.7
—
—
—
0
0
25
61
4.37
9.63
2.7
1.7
—
—
—
0
0
25
62
4.29
9.43
2.0
1.3
—
—
—
0
0
25
62
4.29
9.43
2.0
1.3
—
—
—
0
0
59
262
2.54
8.64
4.0
3.5
—
—
—
0
0
26
72
3.85
8.48
1.5
1.5
—
—
—
0
0
24
63
4.04
8.41
1.5
2.0
185.61
253.23
u/ml
0.39
18
31
20
31
6.81
8.33
7.2
3.4
0.16
0.14
e9/l
0.08
15
26
24
64
3.98
8.24
1.5
2.0
—
—
—
0
0
20
32
6.60
8.16
7.2
3.3
513.20
522.31
e6/l
0.02
15
26
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
26
75
3.69
8.00
3.2
2.4
0.34
0.41
u/ml
0.32
12
37
109
645
2.06
7.98
5.6
2.4
—
—
—
0
0
23
61
3.99
7.95
1.3
1.1
—
—
—
0
0
155
1041
1.97
7.91
2.4
2.0
93.93
94.91
pmol/l
0.09
100
502
62
296
2.36
7.73
7.0
7.2
0.52
1.25
mmol/l
0.81
51
245
90
502
2.11
7.68
4.8
3.0
0.93
0.96
e6/l
0.03
63
296
14
14
10.40
7.61
2.8
3.9
—
—
—
0
0
128
815
1.96
7.54
3.9
3.2
937.35
1200.04
ng/l
0.69
117
692
157
1078
1.91
7.33
3.0
2.6
77.17
77.82
nmol/l
0.10
145
959
109
662
1.99
7.32
2.4
2.5
3.00
3.16
mg/l
0.20
101
570
11
7
16.21
7.28
5.3
4.9
—
—
—
0
0
10
5
20.58
7.18
1.4
1.0
—
—
—
0
0
16
24
6.96
6.90
1.3
1.2
—
—
—
0
0
63
319
2.22
6.80
28.4
6.3
1.91
1.88
mmol/l
0.02
56
254
102
622
1.95
6.67
1.8
1.5
20.08
21.94
nmol/l
0.53
93
519
16
26
6.42
6.55
2.6
1.4
—
—
—
0
0
37
152
2.63
6.30
2.1
1.7
—
—
—
0
0
143
992
1.81
6.14
3.6
3.9
24.21
42.47
ng/l
1.88
110
738
179
1333
1.80
6.01
4.7
3.9
0.00
0.00
estimate
-0.00
46
245
9
6
15.38
5.93
3.7
6.7
—
—
—
0
0
9
6
15.38
5.93
3.7
6.7
—
—
—
0
0
47
224
2.29
5.83
2.7
2.3
7.59
12.89
nmol/l
3.95
38
201
242
1990
1.94
5.75
6.3
4.4
15.93
12.19
mm/h
2.12
227
1818
210
1654
1.81
5.70
5.3
3.3
87.63
51.49
u/l
1.36
195
1526
9
7
13.18
5.61
3.6
1.7
30.89
32.14
u/l
—
9
7
9
7
13.18
5.61
2.9
9.3
—
—
—
0
0
175
1312
1.75
5.58
4.7
3.9
0.00
0.00
estimate
0.50
44
278
174
1319
1.72
5.19
6.4
5.3
0.00
0.00
estimate
-0.00
45
255
14
28
5.18
5.00
1.4
1.2
—
—
—
0
0
18
56
3.35
4.97
2.1
1.6
—
—
—
0
0
78
486
1.80
4.57
1.8
1.7
1132.47
1217.21
nmol/l
0.29
55
360
292
2640
2.51
4.43
40.2
14.6
27.00
24.19
mg/l
0.81
267
2044
113
790
1.67
4.38
2.5
2.1
131.15
205.40
u/l
1.75
106
745
35
167
2.23
4.33
1.8
1.4
—
—
—
0
0
7
6
11.89
4.29
1.1
1.2
—
—
—
0
0
79
508
1.74
4.13
5.5
3.6
65.66
239.82
ng/l
1.54
68
410
9
15
6.14
3.84
2.0
1.1
—
—
—
0
0
22
90
2.55
3.81
2.4
2.4
—
—
—
0
0
11
24
4.71
3.78
1.0
1.0
—
—
—
0
0
9
16
5.76
3.68
4.3
3.4
92.11
94.31
%
—
9
16
19
74
2.67
3.62
1.4
1.2
—
—
—
0
0
17
63
2.80
3.55
1.9
1.5
—
—
—
0
0
11
26
4.35
3.54
1.5
1.6
—
—
—
0
0
6
6
10.16
3.51
2.0
2.8
—
—
—
0
0
13
37
3.62
3.44
5.6
1.6
4.50
8067.33
u/l
—
6
7
44
250
1.88
3.43
3.6
5.9
1.91
1.57
mmol/l
0.20
32
189
13
42
3.19
3.41
2.0
1.6
—
—
—
0
0
9
18
5.11
3.39
4.3
2.9
0.11
0.19
nmol/l
—
9
11
10
23
4.45
3.34
4.3
1.3
0.21
0.14
nmol/l
—
10
13
13
43
3.11
3.29
2.5
1.7
—
—
—
0
0
19
78
2.53
3.28
1.3
1.5
237.21
277.92
ug/g
0.36
13
44
45
262
1.84
3.25
3.5
5.8
5.15
5.08
kpa
0.29
40
252
11
29
3.89
3.21
1.1
1.4
—
—
—
0
0
9
20
4.60
3.13
2.9
1.1
—
—
—
0
0
11
30
3.76
3.11
1.2
1.2
—
—
—
0
0
8
16
5.10
3.07
1.0
1.1
—
—
—
0
0
5
5
10.13
2.99
1.2
1.2
—
—
—
0
0
13
46
2.90
2.95
2.5
1.7
—
—
—
0
0
7
13
5.48
2.88
1.4
1.1
—
—
—
0
0
10
28
3.65
2.81
4.7
2.9
53.36
55.17
u/ml
—
10
28
7
14
5.09
2.74
3.7
1.6
—
—
—
0
0
12
41
3.00
2.65
2.7
1.7
—
—
—
0
0
7
15
4.75
2.61
3.7
1.6
—
—
—
0
0
9
25
3.67
2.59
1.1
1.3
610.56
244.39
u/l
—
9
25
5
7
7.24
2.56
1.6
1.4
326.60
10403.00
u/l
—
5
7
6
11
5.54
2.55
1.3
1.5
—
—
—
0
0
6
11
5.54
2.55
1.3
1.5
—
—
—
0
0
38
227
1.77
2.54
3.9
5.1
95.72
72.84
ng/l
0.49
31
200
11
37
3.04
2.51
2.2
1.7
—
—
—
0
0
228
2017
1.48
2.43
4.8
3.9
14.83
14.82
pmol/l
0.00
211
1816
6
12
5.07
2.41
1.3
1.4
—
—
—
0
0
6
12
5.07
2.41
1.3
1.4
—
—
—
0
0
8
22
3.70
2.38
1.3
1.7
—
—
—
0
0
7
17
4.19
2.37
3.7
1.6
—
—
—
0
0
95
721
1.46
2.33
5.0
4.1
0.00
0.00
estimate
-0.00
43
254
8
23
3.54
2.28
3.8
1.5
—
—
—
0
0
7
19
3.74
2.16
1.7
1.4
—
—
—
0
0
36
223
1.69
2.14
5.6
2.7
67.10
63.44
ml/min/173m2
—
10
88
76
562
1.46
2.12
1.8
1.8
431.92
446.75
pmol/l
0.20
60
461
17
83
2.11
2.05
1.6
1.8
—
—
—
0
0
6
15
4.06
2.05
2.0
2.7
811.00
803.00
u/ml
—
6
15
259
2390
1.48
1.88
35.7
13.6
77.95
78.80
ml/min/173m2
0.29
239
1968
295
2806
1.85
1.86
32.2
10.8
27.40
26.10
u/l
0.67
290
2699
5
12
4.22
1.83
1.2
1.1
—
—
—
0
0
6
18
3.38
1.75
2.5
3.2
30.33
25.50
umol/l
—
6
18
8
30
2.71
1.73
2.5
2.0
—
—
—
0
0
11
48
2.34
1.72
1.1
1.4
—
—
—
0
0
45
313
1.51
1.69
1.6
1.4
—
—
—
0
0
7
25
2.84
1.66
1.0
1.0
—
—
—
0
0
17
91
1.92
1.64
1.8
2.0
—
—
—
0
0
7
26
2.73
1.59
1.0
1.0
—
—
—
0
0
25
153
1.69
1.59
1.2
1.4
—
34.04
—
0
12
5
15
3.37
1.53
3.2
1.7
—
—
—
0
0
7
27
2.63
1.52
1.4
1.2
—
—
—
0
0
12
58
2.11
1.51
51.8
5.5
52.21
66.51
%
1.08
12
58
9
37
2.47
1.49
1.1
1.3
—
—
—
0
0
5
16
3.16
1.44
2.0
1.1
—
—
—
0
0
120
1015
1.30
1.40
4.8
3.9
—
—
—
0
0
7
29
2.45
1.40
1.9
1.1
—
—
—
0
0
17
97
1.80
1.38
1.4
2.2
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
18
2.81
1.29
1.6
1.2
—
—
—
0
0
5
19
2.66
1.22
4.0
3.8
—
—
—
0
0
5
19
2.66
1.22
1.0
1.2
—
—
—
0
0
12
65
1.88
1.15
1.6
1.4
—
—
—
0
0
88
734
1.28
1.12
2.2
1.6
1.52
1.33
mmol/l
1.13
73
611
11
59
1.90
1.08
2.5
3.0
16.18
16.44
%
—
6
33
9
46
1.98
1.04
9.1
3.3
47.44
58.61
%
—
9
46
257
2437
1.30
1.01
5.6
4.7
2.02
1.97
mu/l
0.27
234
2198
7
35
2.02
1.00
1.1
1.1
—
—
—
0
0
266
2535
1.32
1.00
4.9
4.7
4.59
4.61
mmol/l
0.11
243
2329
15
92
1.66
0.99
1.3
1.1
—
—
—
0
0
5
23
2.19
0.98
1.4
1.7
—
—
—
0
0
42
323
1.35
0.96
7.7
7.1
—
—
—
0
0
15
93
1.64
0.95
1.3
1.1
—
—
—
0
0
7
37
1.91
0.94
1.4
1.1
—
—
—
0
0
6
28
2.16
0.92
1.0
1.0
—
—
—
0
0
6
28
2.16
0.92
1.2
1.2
—
—
—
0
0
6
28
2.16
0.92
1.2
1.2
—
—
—
0
0
9
153
0.58
0.91
1.7
1.6
—
—
—
0
0
6
29
2.09
0.90
1.2
1.2
—
—
—
0
0
6
29
2.09
0.90
1.2
1.2
—
—
—
0
0
6
29
2.09
0.90
1.2
1.2
—
—
—
0
0
30
221
1.40
0.89
2.0
2.6
11.03
8.00
ug/l
0.22
24
196
10
168
0.58
0.89
2.0
1.7
—
—
—
0
0
16
103
1.58
0.89
1.8
1.7
—
—
—
0
0
6
30
2.02
0.87
1.3
1.1
—
—
—
0
0
256
2441
1.26
0.85
4.7
4.1
1.49
1.29
mmol/l
3.14
231
2220
13
201
0.63
0.84
3.0
1.8
—
—
—
0
0
10
61
1.66
0.69
1.2
1.3
—
—
—
0
0
262
2522
1.23
0.68
4.8
4.6
1.38
1.47
mmol/l
2.42
237
2299
5
28
1.80
0.66
3.2
3.1
3.82
6.79
umol/l
—
5
22
11
70
1.59
0.66
1.8
1.3
—
—
—
0
0
19
139
1.39
0.62
34.0
4.2
1.22
1.22
%
0.01
19
139
0
22
0.00
0.59
0.0
1.4
—
—
—
0
0
6
35
1.73
0.58
1.8
1.8
—
—
—
0
0
72
633
1.18
0.56
1.3
1.4
0.96
2.27
u/ml
0.75
14
154
254
2453
1.19
0.54
5.9
5.9
39.61
40.17
mmol/mol
0.40
229
2276
168
1577
1.14
0.53
2.8
2.8
—
—
—
0
0
18
135
1.35
0.52
35.8
4.2
0.55
0.67
%
0.99
18
135
9
64
1.42
0.52
1.1
1.3
—
—
—
0
0
6
40
1.51
0.52
1.8
4.2
—
—
—
0
0
260
2526
1.17
0.46
4.9
4.7
5.96
6.02
mmol/l
0.29
236
2282
0
15
0.00
0.41
0.0
1.9
—
—
—
0
0
17
132
1.30
0.41
1.2
1.2
—
—
—
0
0
90
824
1.13
0.41
3.7
3.8
9.88
29.82
mg/mmol
0.44
52
513
297
2926
1.28
0.39
64.5
21.6
37.83
40.10
%
7.31
284
2755
297
2927
1.27
0.38
62.4
21.5
4.19
4.49
e12/l
16.78
292
2843
5
37
1.36
0.37
1.2
1.1
—
—
—
0
0
9
71
1.28
0.36
1.1
1.4
—
—
—
0
0
264
2582
1.14
0.34
5.2
5.2
2.74
2.70
mmol/l
0.21
240
2360
6
45
1.34
0.34
1.2
1.1
—
—
—
0
0
11
84
1.32
0.30
1.2
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.8
—
—
—
0
0
56
520
1.09
0.21
3.1
3.0
0.93
0.74
ug/l
0.27
40
331
39
423
0.91
0.18
1.4
1.3
5.43
8.76
u/ml
0.29
15
153
7
61
1.15
0.17
2.1
1.9
169.29
223.45
pmol/l
—
7
55
50
469
1.08
0.15
1.7
1.7
—
—
—
0
0
92
893
1.04
0.10
6.0
4.9
2.85
2.59
ug/l
0.10
79
805
5
44
1.14
0.10
1.2
1.3
—
—
—
0
0
17
156
1.09
0.08
1.0
1.1
—
—
—
0
0
70
713
0.98
0.03
3.6
4.3
21.76
21.39
%
0.04
27
329
32
329
0.97
0.02
4.5
4.6
31.84
32.22
%
0.05
19
211
43
438
0.98
0.01
1.5
1.3
58.04
33.15
iu/ml
—
10
145
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_DRUGPOLY and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_DRUGPOLY | 4.185 [3.26, 5.37] | < 0.001 |
| Birth year | 0.996 [0.98, 1.01] | 0.502 |
During the follow-up period (1.1.1998 — 31.12.2019), 289 out of 698 females with G6_DRUGPOLY died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_DRUGPOLY | 2.961 [2.28, 3.84] | < 0.001 |
| Birth year | 0.99 [0.98, 1.0] | 0.032 |
During the follow-up period (1.1.1998 — 31.12.2019), 218 out of 581 males with G6_DRUGPOLY died.
Mortality risk
Mortality risk for people of age
years, who have G6_DRUGPOLY.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.486% | 0.586% |
| 5 | 2.514% | 3.499% |
| 10 | 6.052% | 8.655% |
| 15 | 11.118% | 16.382% |
| 20 | 19.482% | 27.032% |
Relationships between endpoints
↥Index endpoint: G6_DRUGPOLY – Drug-induced polyneuropathy
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data